8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Feb 13, 2026·SEC
IDEXX Laboratories, Inc.(IDXX)Earnings, Financials & Key Ratios
IDXX•NASDAQ
43.0× P/E·Price updated Jun 19, 2026
AboutIDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.Show more
- Revenue$4.3B+10.4%
- EBITDA$1.47B+16.5%
- Net Income$1.06B+19.3%
- EPS (Diluted)13.08+22.6%
- Gross Margin61.8%+1.2%
- EBITDA Margin34.08%+5.5%
- Operating Margin31.6%+9.2%
- Net Margin24.62%+8.1%
- ROE66.2%+14.8%
IDXX Key Insights
IDEXX Laboratories, Inc. (IDXX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 68.2%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 24.5% free cash flow margin
- ✓Share count reduced 3.1% through buybacks
- ✓Healthy 5Y average net margin of 22.8%
- ✓Efficient asset utilization: 1.3x turnover
✗Weaknesses
- ✗Expensive at 28.2x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IDXX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IDXX Price & Volume
IDEXX Laboratories, Inc. (IDXX) stock price & volume — 10-year historical chart
Loading chart...
IDXX Growth Metrics
IDEXX Laboratories, Inc. (IDXX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.39%
5 Years9.72%
3 Years8.52%
TTM13.08%
Profit CAGR
10 Years18.62%
5 Years12.74%
3 Years15.98%
TTM22.38%
EPS CAGR
10 Years20.36%
5 Years14.28%
3 Years17.66%
TTM25.32%
Return on Capital
10 Years57.6%
5 Years56.03%
3 Years56.22%
Last Year61.44%
IDXX Recent Earnings
IDEXX Laboratories, Inc. (IDXX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$3.47+1.8%
$3.41
Rev
$1.1B+2.0%
$1.1B
Q1 2026
Feb 2, 2026Metric
Actual
Est
EPS
$3.08+5.1%
$2.93
Rev
$1.1B+1.7%
$1.1B
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$3.40+8.3%
$3.14
Rev
$1.1B+3.0%
$1.1B
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$3.63+10.7%
$3.28
Rev
$1.1B+4.4%
$1.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $3.47vs $3.41+1.8% | $1.1Bvs $1.1B+2.0% |
| Q1 2026 | Feb 2, 2026 | $3.08vs $2.93+5.1% | $1.1Bvs $1.1B+1.7% |
| Q4 2025 | Nov 3, 2025 | $3.40vs $3.14+8.3% | $1.1Bvs $1.1B+3.0% |
| Q3 2025 | Aug 4, 2025 | $3.63vs $3.28+10.7% | $1.1Bvs $1.1B+4.4% |
Based on last 12 quarters of dataView full earnings history →
IDXX Peer Comparison
IDEXX Laboratories, Inc. (IDXX) competitors in Food, Water and Veterinary Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZTS | 33B | 78.71 | 13.07 | 2.28% | 27.79% | 62.41% | 2.85 | |
 HSIC | 9.17B | 79.92 | 24.44 | 4.03% | 3.02% | 8.24% | 0.77 | |
 ELAN | 12.1B | 24.22 | -51.53 | 6.22% | -4.95% | -3.64% | 0.61 | |
 ANIP | 1.81B | 79.49 | 23.94 | 43.78% | 9.71% | 17.32% | 0.60 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 CHWY | 7.54B | 18.21 | 35.02 | 6.24% | 1.57% | 44.82% | 1.12 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 | |
 BIO | 7.63B | 282.44 | 10.13 | 0.65% | 6.52% | 2.4% | 0.21 |
Compare IDXX vs Peers
IDEXX Laboratories, Inc. (IDXX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IDXX Income Statement
IDEXX Laboratories, Inc. (IDXX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.97B | 2.21B | 2.41B | 2.71B | 3.22B | 3.37B | 3.66B | 3.9B | 4.3B | 4.45B |
Revenue Growth % | 10.91% | 12.4% | 8.75% | 12.45% | 18.79% | 4.73% | 8.72% | 6.46% | 10.42% | 13.08% |
Cost of Goods Sold | 871.68M | 971.7M | 1.04B | 1.14B | 1.33B | 1.36B | 1.47B | 1.52B | 1.64B | 1.69B |
COGS % of Revenue | 44.27% | 43.9% | 43.27% | 41.96% | 41.24% | 40.48% | 40.18% | 38.96% | 38.2% | - |
Gross Profit | 1.1B▲ 0% | 1.24B▲ 13.1% | 1.37B▲ 10.0% | 1.57B▲ 15.0% | 1.89B▲ 20.3% | 2B▲ 6.1% | 2.19B▲ 9.3% | 2.38B▲ 8.6% | 2.66B▲ 11.8% | 2.76B▲ 0% |
Gross Margin % | 55.73% | 56.1% | 56.73% | 58.04% | 58.76% | 59.52% | 59.82% | 61.04% | 61.8% | 62.05% |
Gross Profit Growth % | 12.5% | 13.14% | 9.99% | 15.05% | 20.27% | 6.08% | 9.26% | 8.63% | 11.8% | - |
Operating Expenses | 684.35M | 750.21M | 812.7M | 876.52M | 957.4M | 1.11B | 1.09B | 1.25B | 1.3B | 1.35B |
OpEx % of Revenue | 34.76% | 33.9% | 33.77% | 32.38% | 29.78% | 32.83% | 29.85% | 32.09% | 30.2% | - |
Selling, General & Admin | 575.17M | 632.34M | 679.51M | 735.27M | 796.39M | 850.75M | 901.89M | 1.03B | 1.05B | 1.09B |
SG&A % of Revenue | 29.21% | 28.57% | 28.23% | 27.17% | 24.77% | 25.26% | 24.64% | 26.45% | 24.36% | - |
Research & Development | 109.18M | 117.86M | 133.19M | 141.25M | 161.01M | 254.82M | 190.95M | 219.79M | 251.21M | 257.93M |
R&D % of Revenue | 5.54% | 5.33% | 5.53% | 5.22% | 5.01% | 7.57% | 5.22% | 5.64% | 5.84% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 1.46M | 2.2M | 0 | 0 | 0 | 0 |
Operating Income | 413.03M▲ 0% | 491.33M▲ 19.0% | 552.85M▲ 12.5% | 694.52M▲ 25.6% | 932.03M▲ 34.2% | 898.76M▼ 3.6% | 1.1B▲ 22.1% | 1.13B▲ 2.8% | 1.36B▲ 20.5% | 1.41B▲ 0% |
Operating Margin % | 20.98% | 22.2% | 22.97% | 25.66% | 28.99% | 26.69% | 29.97% | 28.95% | 31.6% | 31.63% |
Operating Income Growth % | 17.93% | 18.96% | 12.52% | 25.63% | 34.2% | -3.57% | 22.07% | 2.84% | 20.53% | - |
EBITDA | 496.17M | 574.51M | 640.86M | 790.52M | 1.04B | 1.01B | 1.21B | 1.26B | 1.47B | 1.52B |
EBITDA Margin % | 25.2% | 25.96% | 26.63% | 29.21% | 32.24% | 30.01% | 33.11% | 32.28% | 34.08% | 34.12% |
EBITDA Growth % | 15.8% | 15.79% | 11.55% | 23.35% | 31.13% | -2.5% | 19.92% | 3.81% | 16.55% | 18.53% |
D&A (Non-Cash Add-back) | 83.14M | 83.18M | 88.01M | 96M | 104.6M | 111.9M | 114.91M | 129.94M | 106.46M | 111.12M |
EBIT | 418.28M | 492.49M | 553.27M | 695.11M | 932.46M | 899.83M | 1.1B | 1.14B | 1.36B | 1.41B |
Net Interest Income | -31.97M | -33.59M | -30.63M | -32.54M | -29.37M | -38.79M | -35.95M | -18.51M | -35.84M | -37.84M |
Interest Income | 5.25M | 1.15M | 427K | 586K | 434K | 1.06M | 5.63M | 12.7M | 2.42M | 1.79M |
Interest Expense | 37.23M | 34.74M | 31.05M | 33.13M | 29.81M | 39.86M | 41.58M | 31.2M | 38.27M | 39.64M |
Other Income/Expense | -31.97M | -33.59M | -30.63M | -32.54M | -29.37M | -38.79M | -35.95M | -18.51M | -35.84M | -36.54M |
Pretax Income | 381.06M▲ 0% | 457.74M▲ 20.1% | 522.22M▲ 14.1% | 661.99M▲ 26.8% | 902.65M▲ 36.4% | 859.97M▼ 4.7% | 1.06B▲ 23.4% | 1.11B▲ 4.6% | 1.32B▲ 19.3% | 1.37B▲ 0% |
Pretax Margin % | 19.35% | 20.68% | 21.7% | 24.46% | 28.07% | 25.54% | 28.99% | 28.48% | 30.77% | 30.8% |
Income Tax | 117.79M | 80.69M | 94.43M | 79.85M | 157.81M | 180.88M | 216.13M | 221.96M | 264.73M | 274.31M |
Effective Tax Rate % | 30.91% | 17.63% | 18.08% | 12.06% | 17.48% | 21.03% | 20.37% | 20% | 19.99% | 20.03% |
Net Income | 263.14M▲ 0% | 377.03M▲ 43.3% | 427.72M▲ 13.4% | 581.78M▲ 36.0% | 744.85M▲ 28.0% | 679.09M▼ 8.8% | 845.04M▲ 24.4% | 887.87M▲ 5.1% | 1.06B▲ 19.3% | 1.1B▲ 0% |
Net Margin % | 13.36% | 17.04% | 17.77% | 21.49% | 23.17% | 20.17% | 23.08% | 22.78% | 24.62% | 24.63% |
Net Income Growth % | 18.51% | 43.28% | 13.44% | 36.02% | 28.03% | -8.83% | 24.44% | 5.07% | 19.33% | 22.38% |
Net Income (Continuing) | 263.27M | 377.05M | 427.79M | 582.13M | 744.84M | 679.09M | 845.04M | 887.87M | 1.06B | 1.1B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 264K | 280K | 352K | 707K | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.94▲ 0% | 4.26▲ 44.9% | 4.89▲ 14.8% | 6.71▲ 37.2% | 8.60▲ 28.2% | 8.03▼ 6.6% | 10.06▲ 25.3% | 10.67▲ 6.1% | 13.08▲ 22.6% | 13.58▲ 0% |
EPS Growth % | 20.49% | 44.9% | 14.79% | 37.22% | 28.17% | -6.63% | 25.28% | 6.06% | 22.59% | 25.32% |
EPS (Basic) | 3.00 | 4.34 | 4.97 | 6.82 | 8.74 | 8.12 | 10.17 | 10.77 | 13.17 | - |
Diluted Shares Outstanding | 89.57M | 88.47M | 87.54M | 86.72M | 86.57M | 84.6M | 83.98M | 83.25M | 80.67M | 80.67M |
Basic Shares Outstanding | 87.77M | 86.86M | 86.11M | 85.34M | 85.2M | 83.62M | 83.07M | 82.47M | 80.1M | 80.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IDXX Balance Sheet
IDEXX Laboratories, Inc. (IDXX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 971.99M | 654.17M | 679.64M | 1.06B | 955.65M | 1.1B | 1.5B | 1.4B | 1.34B | 1.45B |
Cash & Short-Term Investments | 471.93M | 123.79M | 90.33M | 383.93M | 144.45M | 112.55M | 453.93M | 288.27M | 180.07M | 200.53M |
Cash Only | 187.68M | 123.79M | 90.33M | 383.93M | 144.45M | 112.55M | 453.93M | 288.27M | 180.07M | 200.53M |
Short-Term Investments | 284.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 270.07M | 258.52M | 307.49M | 374.74M | 425.58M | 490.9M | 529.53M | 561.32M | 693.19M | 603.54M |
Days Sales Outstanding | 50.06 | 42.63 | 46.63 | 50.53 | 48.31 | 53.21 | 52.79 | 52.57 | 58.79 | 54.9 |
Inventory | 164.32M | 173.3M | 195.02M | 209.87M | 269.03M | 367.82M | 380.28M | 381.88M | 377.76M | 382.4M |
Days Inventory Outstanding | 68.81 | 65.1 | 68.35 | 67.46 | 74.06 | 98.5 | 94.36 | 91.79 | 83.86 | 83.52 |
Other Current Assets | 101.14M | 54.14M | 54.81M | 59.64M | 74.59M | 88.46M | 83.14M | 109.81M | 31.35M | 267.6M |
Total Non-Current Assets | 741.43M | 883.18M | 1.15B | 1.23B | 1.48B | 1.65B | 1.76B | 1.89B | 2.01B | 1.93B |
Property, Plant & Equipment | 379.1M | 437.27M | 614.45M | 646.34M | 692.77M | 768.09M | 817.68M | 829.25M | 870.61M | 740.38M |
Fixed Asset Turnover | 5.19x | 5.06x | 3.92x | 4.19x | 4.64x | 4.38x | 4.48x | 4.70x | 4.94x | 5.31x |
Goodwill | 199.87M | 214.49M | 239.72M | 243.35M | 359.35M | 361.8M | 365.96M | 405.1M | 414M | 412.1M |
Intangible Assets | 43.85M | 41.83M | 58.47M | 52.54M | 99.03M | 97.67M | 84.5M | 111.68M | 109.84M | 104.75M |
Long-Term Investments | 9.95M | 10.89M | 13.66M | 12.06M | 18.6M | 55.5M | 56.19M | 57.72M | 297.09M | 632.04M |
Other Non-Current Assets | 100.97M | 170.22M | 218.44M | 245.98M | 287.02M | 307.01M | 332.98M | 364.17M | 291.08M | 674.19M |
Total Assets | 1.71B▲ 0% | 1.54B▼ 10.3% | 1.83B▲ 19.2% | 2.29B▲ 25.2% | 2.44B▲ 6.2% | 2.75B▲ 12.7% | 3.26B▲ 18.7% | 3.29B▲ 1.0% | 3.35B▲ 1.7% | 3.39B▲ 0% |
Asset Turnover | 1.15x | 1.44x | 1.31x | 1.18x | 1.32x | 1.23x | 1.12x | 1.18x | 1.28x | 1.32x |
Asset Growth % | 11.94% | -10.28% | 19.2% | 25.22% | 6.22% | 12.7% | 18.68% | 1.03% | 1.74% | 5.7% |
Total Current Liabilities | 1B | 770.44M | 725.34M | 582.76M | 763.58M | 1.24B | 951.55M | 1.07B | 1.15B | 1.3B |
Accounts Payable | 66.97M | 69.53M | 72.17M | 74.56M | 116.14M | 110.22M | 110.64M | 114.21M | 110.41M | 129.97M |
Days Payables Outstanding | 28.04 | 26.12 | 25.3 | 23.96 | 31.97 | 29.52 | 27.45 | 27.45 | 24.51 | 25.92 |
Short-Term Debt | 655M | 398.94M | 288.76M | 49.99M | 148.5M | 653.98M | 325M | 417.79M | 500.07M | 680M |
Deferred Revenue (Current) | 29.18M | 41.29M | 41.46M | 42.57M | 40.03M | 37.94M | 37.2M | 33.8M | 35.26M | 143.61M |
Other Current Liabilities | 102.94M | 109.49M | 127.17M | 167.65M | 182.93M | 142.99M | 174.38M | 174.58M | 201.96M | 0 |
Current Ratio | 0.97x | 0.85x | 0.94x | 1.82x | 1.25x | 0.89x | 1.57x | 1.31x | 1.17x | 1.12x |
Quick Ratio | 0.80x | 0.62x | 0.67x | 1.46x | 0.90x | 0.59x | 1.17x | 0.95x | 0.84x | 0.82x |
Cash Conversion Cycle | 90.83 | 81.61 | 89.69 | 94.03 | 90.4 | 122.2 | 119.7 | 116.9 | 118.14 | 112.51 |
Total Non-Current Liabilities | 762.69M | 776.14M | 929.31M | 1.08B | 983.63M | 902.23M | 823.85M | 630.21M | 596.56M | 529.54M |
Long-Term Debt | 606.08M | 601.35M | 698.91M | 858.49M | 775.21M | 694.39M | 622.88M | 449.79M | 475.99M | 299.85M |
Capital Lease Obligations | 0 | 0 | 67.47M | 77.04M | 87.38M | 101.24M | 99.67M | 97.84M | 101.15M | 414.03M |
Deferred Tax Liabilities | 25.35M | 29.27M | 33.02M | 11.71M | 8.94M | 8.15M | 7.24M | 11.31M | 31.86M | 82.27M |
Other Non-Current Liabilities | 95.72M | 84.83M | 81.16M | 85.6M | 70.94M | 67.59M | 65.53M | 44.34M | -44.62M | 54.03M |
Total Liabilities | 1.77B | 1.55B | 1.65B | 1.66B | 1.75B | 2.14B | 1.78B | 1.7B | 1.75B | 1.83B |
Total Debt | 1.26B | 1B | 1.07B | 1B | 1.03B | 1.47B | 1.07B | 986.95M | 1.08B | 1.08B |
Net Debt | 1.07B | 876.49M | 980.1M | 619.32M | 886.55M | 1.36B | 613.42M | 698.68M | 897.14M | 878.07M |
Debt / Equity | - | - | 6.02x | 1.59x | 1.49x | 2.41x | 0.72x | 0.62x | 0.67x | 0.69x |
Debt / EBITDA | 2.54x | 1.74x | 1.67x | 1.27x | 0.99x | 1.45x | 0.88x | 0.78x | 0.73x | 0.71x |
Net Debt / EBITDA | 2.16x | 1.53x | 1.53x | 0.78x | 0.86x | 1.34x | 0.51x | 0.56x | 0.61x | 0.58x |
Interest Coverage | 11.24x | 14.17x | 17.82x | 20.98x | 31.28x | 22.58x | 26.52x | 36.57x | 35.61x | 35.55x |
Total Equity | -53.84M▲ 0% | -9.23M▲ 82.9% | 177.82M▲ 2026.0% | 632.79M▲ 255.9% | 689.99M▲ 9.0% | 608.74M▼ 11.8% | 1.48B▲ 143.9% | 1.6B▲ 7.5% | 1.61B▲ 0.6% | 1.56B▲ 0% |
Equity Growth % | 50.24% | 82.85% | 2025.97% | 255.85% | 9.04% | -11.78% | 143.87% | 7.46% | 0.63% | -3.1% |
Book Value per Share | -0.60 | -0.10 | 2.03 | 7.30 | 7.97 | 7.20 | 17.68 | 19.16 | 19.90 | 19.29 |
Total Shareholders' Equity | -54.11M | -9.51M | 177.47M | 632.09M | 689.99M | 608.74M | 1.48B | 1.6B | 1.61B | 1.56B |
Common Stock | 10.43M | 10.51M | 10.57M | 10.65M | 10.69M | 10.72M | 10.75M | 10.78M | 10.84M | 10.85M |
Retained Earnings | 803.54M | 1.17B | 1.6B | 2.18B | 2.92B | 3.6B | 4.44B | 5.33B | 6.39B | 6.67B |
Treasury Stock | -1.91B | -2.29B | -2.6B | -2.8B | -3.57B | -4.39B | -4.47B | -5.33B | -6.56B | -6.93B |
Accumulated OCI | -36.47M | -41.79M | -46.18M | -53.62M | -53.48M | -77.8M | -71.21M | -93.64M | -62.75M | -64.94M |
Minority Interest | 264K | 280K | 352K | 707K | 0 | 0 | 0 | 0 | 0 | 0 |
IDXX Cash Flow Statement
IDEXX Laboratories, Inc. (IDXX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 373.28M | 400.08M | 459.16M | 648.06M | 755.55M | 542.98M | 906.51M | 929M | 1.18B | 940.11M |
Operating CF Margin % | 18.96% | 18.08% | 19.08% | 23.94% | 23.5% | 16.13% | 24.76% | 23.84% | 27.37% | - |
Operating CF Growth % | 11.57% | 7.18% | 14.77% | 41.14% | 16.59% | -28.13% | 66.95% | 2.48% | 26.81% | -8.03% |
Net Income | 263.27M | 377.05M | 427.79M | 582.13M | 744.84M | 679.09M | 845.04M | 887.87M | 1.06B | 1.1B |
Depreciation & Amortization | 83.14M | 83.18M | 88.01M | 96M | 104.6M | 111.9M | 114.91M | 129.94M | 145.18M | 4.66M |
Stock-Based Compensation | 23.52M | 25.16M | 39.28M | 30.95M | 37.76M | 49.77M | 59.74M | 60.3M | 0 | -14.62M |
Deferred Taxes | -7.92M | 1.21M | 6.16M | -38.08M | -3.38M | -35.06M | -48.31M | -24.19M | 131.2M | 27.58M |
Other Non-Cash Items | 2.89M | 5.13M | 2.88M | 8.83M | 9.25M | 10.82M | 7.56M | 8.34M | 69.73M | 117.78M |
Working Capital Changes | 8.38M | -91.64M | -104.97M | -31.76M | -137.52M | -273.53M | -72.43M | -133.24M | -227.51M | -12.08M |
Change in Receivables | -24.92M | -18.4M | -22.47M | -60.72M | -33.14M | -41.4M | -53.87M | -28.28M | -68.72M | 59.1M |
Change in Inventory | -19.06M | -25.62M | -37.31M | -18.89M | -52.92M | -121.73M | -28.65M | -28M | -789K | -750K |
Change in Payables | 1.39M | -166K | 1.96M | 981K | 11.23M | 3.47M | -557K | 8.09M | -8.57M | 4.53M |
Cash from Investing | -138.69M | 138.6M | -205.53M | -109.38M | -292.97M | -195.35M | -125.25M | -207.06M | -136.24M | -106.63M |
Capital Expenditures | -76.7M | -122.94M | -155.22M | -107.63M | -119.55M | -148.84M | -133.63M | -120.92M | -138.23M | -94.85M |
CapEx % of Revenue | 3.9% | 5.55% | 6.45% | 3.98% | 3.72% | 4.42% | 3.65% | 3.1% | 3.21% | 2.13% |
Acquisitions | -14.58M | -22.5M | -50.3M | -1.75M | -173.42M | -46.51M | 0 | -77.7M | 0 | -2.6M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -46.51M | 8.38M | -10M | 2.74M | -9.18M |
Cash from Financing | -208.02M | -597.8M | -286.41M | -248.42M | -697.41M | -370.94M | -442M | -878.07M | -1.16B | -830.9M |
Debt Issued (Net) | 44M | -256.04M | -10.28M | -94.65M | 23.5M | 430.5M | -404M | -75M | -30.39M | -99.89M |
Equity Issued (Net) | -252.02M | -331.12M | -265.55M | -131.49M | -700.21M | -783.96M | -24.89M | -792.54M | -1.12B | -805.4M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -290.64M | -369.32M | -301.66M | -182.81M | -746.78M | -819.71M | -71.92M | -837.03M | -1.22B | -816.07M |
Other Financing | 0 | -10.64M | -10.43M | -22.28M | -20.7M | -17.04M | -13.11M | -10.53M | -7.24M | 74.38M |
Net Change in Cash | 32.77M▲ 0% | -63.88M▼ 294.9% | -33.47M▲ 47.6% | 293.6M▲ 977.3% | -239.47M▼ 181.6% | -31.91M▲ 86.7% | 341.39M▲ 1169.9% | -165.67M▼ 148.5% | -108.2M▲ 34.7% | 36.56M▲ 0% |
Free Cash Flow | 296.57M▲ 0% | 277.15M▼ 6.5% | 303.93M▲ 9.7% | 540.44M▲ 77.8% | 636M▲ 17.7% | 394.15M▼ 38.0% | 772.88M▲ 96.1% | 798.08M▲ 3.3% | 1.05B▲ 32.0% | 845.46M▲ 0% |
FCF Margin % | 15.06% | 12.52% | 12.63% | 19.97% | 19.78% | 11.71% | 21.11% | 20.48% | 24.48% | 19.02% |
FCF Growth % | 9.93% | -6.55% | 9.66% | 77.81% | 17.68% | -38.03% | 96.09% | 3.26% | 31.99% | 0.93% |
FCF per Share | 3.31 | 3.13 | 3.47 | 6.23 | 7.35 | 4.66 | 9.20 | 9.59 | 13.06 | 10.48 |
FCF Conversion (FCF/Net Income) | 1.42x | 1.06x | 1.07x | 1.11x | 1.01x | 0.80x | 1.07x | 1.05x | 1.11x | 0.77x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IDXX Key Ratios
IDEXX Laboratories, Inc. (IDXX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | 507.4% | 143.54% | 112.62% | 104.58% | 80.74% | 57.66% | 66.2% | 70.87% |
Return on Invested Capital (ROIC) | 31.6% | 39.06% | 40.95% | 43.23% | 49.42% | 38.05% | 40.49% | 38.54% | 42.53% | 42.46% |
Gross Margin | 55.73% | 56.1% | 56.73% | 58.04% | 58.76% | 59.52% | 59.82% | 61.04% | 61.8% | 62.05% |
Net Margin | 13.36% | 17.04% | 17.77% | 21.49% | 23.17% | 20.17% | 23.08% | 22.78% | 24.62% | 24.63% |
Debt / Equity | - | - | 6.02x | 1.59x | 1.49x | 2.41x | 0.72x | 0.62x | 0.67x | 0.69x |
Interest Coverage | 11.24x | 14.17x | 17.82x | 20.98x | 31.28x | 22.58x | 26.52x | 36.57x | 35.61x | 35.55x |
FCF Conversion | 1.42x | 1.06x | 1.07x | 1.11x | 1.01x | 0.80x | 1.07x | 1.05x | 1.11x | 0.77x |
Revenue Growth | 10.91% | 12.4% | 8.75% | 12.45% | 18.79% | 4.73% | 8.72% | 6.46% | 10.42% | 13.08% |
Related:IDXX Dividend History·IDXX Revenue History·IDXX Price History·IDXX P/E History·IDXX Financial Ratios·IDXX Institutional Holders
IDXX SEC Filings & Documents
IDEXX Laboratories, Inc. (IDXX) SEC filings — annual & quarterly reports (10-K, 10-Q)
IDXX Frequently Asked Questions
IDEXX Laboratories, Inc. (IDXX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IDEXX Laboratories, Inc. (IDXX) reported $4.45B in revenue for fiscal year 2025. This represents a 1561% increase from $267.7M in 1996.
IDEXX Laboratories, Inc. (IDXX) grew revenue by 10.4% over the past year. This is steady growth.
Yes, IDEXX Laboratories, Inc. (IDXX) is profitable, generating $1.10B in net income for fiscal year 2025 (24.6% net margin).
Dividend & Returns
IDEXX Laboratories, Inc. (IDXX) has a return on equity (ROE) of 66.2%. This is excellent, indicating efficient use of shareholder capital.
IDEXX Laboratories, Inc. (IDXX) generated $845.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.